Everett Harris & Co. CA held its position in shares of Laboratory Corporation of America Holdings (NYSE:LH) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 16,225 shares of the medical research company’s stock at the end of the second quarter. Everett Harris & Co. CA’s holdings in Laboratory Corporation of America Holdings were worth $2,501,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Legal & General Group Plc boosted its position in shares of Laboratory Corporation of America Holdings by 3.1% in the second quarter. Legal & General Group Plc now owns 563,364 shares of the medical research company’s stock valued at $86,825,000 after buying an additional 17,023 shares during the last quarter. SFE Investment Counsel boosted its position in shares of Laboratory Corporation of America Holdings by 39.8% in the second quarter. SFE Investment Counsel now owns 11,959 shares of the medical research company’s stock valued at $1,843,000 after buying an additional 3,406 shares during the last quarter. State of Wisconsin Investment Board boosted its position in shares of Laboratory Corporation of America Holdings by 12.9% in the second quarter. State of Wisconsin Investment Board now owns 179,286 shares of the medical research company’s stock valued at $27,635,000 after buying an additional 20,510 shares during the last quarter. Fiduciary Financial Services of The Southwest Inc. TX boosted its position in shares of Laboratory Corporation of America Holdings by 2.3% in the second quarter. Fiduciary Financial Services of The Southwest Inc. TX now owns 2,200 shares of the medical research company’s stock valued at $339,000 after buying an additional 50 shares during the last quarter. Finally, Morningstar Investment Services LLC boosted its position in shares of Laboratory Corporation of America Holdings by 6.1% in the second quarter. Morningstar Investment Services LLC now owns 65,477 shares of the medical research company’s stock valued at $10,093,000 after buying an additional 3,776 shares during the last quarter. 91.64% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at 156.44 on Thursday. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The firm’s 50-day moving average is $155.79 and its 200-day moving average is $144.84. The stock has a market capitalization of $15.93 billion, a price-to-earnings ratio of 21.91 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The business’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.36 EPS. On average, equities research analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Laboratory Corporation of America Holdings (LH) Stake Maintained by Everett Harris & Co. CA” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/17/laboratory-corporation-of-america-holdings-lh-stake-maintained-by-everett-harris-co-ca.html.

Several research analysts have recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Barclays PLC boosted their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Craig Hallum restated a “buy” rating and issued a $179.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Finally, Credit Suisse Group lowered shares of Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 price objective on the stock. in a report on Thursday, July 13th. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Laboratory Corporation of America Holdings presently has a consensus rating of “Buy” and a consensus price target of $159.75.

In related news, CFO Glenn A. Eisenberg sold 5,968 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $159.46, for a total transaction of $951,657.28. Following the completion of the transaction, the chief financial officer now owns 18,122 shares in the company, valued at approximately $2,889,734.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Lance Berberian sold 3,613 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $139.84, for a total value of $505,241.92. Following the transaction, the senior vice president now owns 5,789 shares of the company’s stock, valued at approximately $809,533.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,681 shares of company stock valued at $2,743,227. Insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.